a slight significancep=0.05
Immunotherapy showed an improved survival compared with all other therapies (Chemotherapy, Local therapy and no targeted therapy) (p=0.001) ( Figure 2A ); for Ipilimumab and combined target therapy compared with all other therapies a slight significance were observed (p=0.05) (see Figure 2B ).